89bio (ETNB) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and 89bio (NASDAQ:ETNB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.

Does the media favor CPRX or ETNB?

In the previous week, 89bio had 9 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 14 mentions for 89bio and 5 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.76 beat 89bio's score of 0.14 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
89bio	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more risk and volatility, CPRX or ETNB?

Catalyst Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, 89bio has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Do analysts rate CPRX or ETNB?

Catalyst Pharmaceuticals presently has a consensus price target of $32.86, indicating a potential upside of 44.24%. 89bio has a consensus price target of $30.33, indicating a potential upside of 380.72%. Given 89bio's higher probable upside, analysts clearly believe 89bio is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
89bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Does the MarketBeat Community prefer CPRX or ETNB?

Catalyst Pharmaceuticals received 389 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 74.89% of users gave Catalyst Pharmaceuticals an outperform vote while only 64.12% of users gave 89bio an outperform vote.

Company	Underperform	Outperform
Catalyst Pharmaceuticals	Outperform Votes 498 74.89%	Underperform Votes 167 25.11%
89bio	Outperform Votes 109 64.12%	Underperform Votes 61 35.88%

Which has better valuation & earnings, CPRX or ETNB?

Catalyst Pharmaceuticals has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$460.48M	5.90	$71.41M	$1.18	19.31
89bio	N/A	N/A	-$142.19M	-$2.91	-2.17

Do insiders & institutionals believe in CPRX or ETNB?

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of 89bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is CPRX or ETNB more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to 89bio's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat 89bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%
89bio	N/A	-59.58%	-52.21%

Summary

Catalyst Pharmaceuticals beats 89bio on 14 of the 18 factors compared between the two stocks.